GlassScriptPhysician profile
Priya Bakaya
NPI 1265693931
$9,868.00
in general payments reported to CMS, 2019-2025
50 companies · $1,646 in 2025
The $1,646 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,200 · 2020: $600 · 2021: $384 · 2022: $1,263 · 2023: $1,942 · 2024: $1,833 · 2025: $1,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,164 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,164.45 |
| Education | $257.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,593.19 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $842.42 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Jazz Pharmaceuticals INC. | $537.12 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.53 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $459.48 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $424.40 | 2019-2025 | |
| Genzyme Corporation | $409.50 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $349.88 | 2020-2025 | Glassia, Cuvitru, Hyqvia |
| Harmony Biosciences LLC | $269.72 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $267.59 | 2023-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $238.25 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $210.14 | 2019-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $172.81 | 2019-2020 | |
| Grifols USA, LLC | $166.19 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Pfizer INC. | $161.18 | 2022-2024 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $156.47 | 2023-2024 | |
| Verona Pharma, INC. | $154.77 | 2025 | Ohtuvayre |
| Insmed, INC. | $148.27 | 2020-2025 | Arikayce, Brinsupri |
| Electromed, INC. | $137.21 | 2022-2025 | Smartvest |
| Zoll Respicardia, INC. | $120.93 | 2024-2025 | Remede System |
| Amgen INC. | $117.68 | 2022-2025 | Tezspire |
| Lilly USA, LLC | $116.58 | 2023-2025 | Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $104.84 | 2019-2020 | |
| Mylan Specialty L.P. | $104.39 | 2019-2024 | Yupelri |
| Mallinckrodt Enterprises LLC | $90.55 | 2019 | |
| Philips North America LLC | $90.16 | 2019-2024 | (O58) Sleep Respiratory Care Und, (Ak6) Vest Therapy |
| Merck Sharp & Dohme LLC | $88.73 | 2019-2025 | Winrevair |
| Axsome Therapeutics, INC. | $81.65 | 2023-2025 | Sunosi |
| Alexion Pharmaceuticals, INC. | $80.27 | 2022-2025 | Ultomiris |
| Azurity Pharmaceuticals, INC. | $77.03 | 2025 | Alvesco, Horizant |
| Baxter Healthcare | $74.63 | 2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Csl Behring | $72.00 | 2019-2025 | Hizentra |
| Gilead Sciences, INC. | $64.45 | 2022 | |
| Boston Scientific Corporation | $55.28 | 2022 | |
| Genentech USA, INC. | $53.38 | 2024 | Xolair |
| Phadia US INC. | $32.23 | 2019 | |
| Shire North American Group INC | $30.60 | 2019 | |
| Viatris Specialty LLC | $29.61 | 2025 | Yupelri |
| United Therapeutics Corporation | $23.31 | 2023 | |
| Covis Pharma Gmbh | $21.94 | 2022 | |
| Vapotherm INC | $21.63 | 2022 | |
| Resmed Corp | $20.90 | 2025 | |
| Vifor Pharma, INC. | $18.78 | 2024 | Zemaira |
| Bayer Healthcare Pharmaceuticals INC. | $16.63 | 2019 | |
| Abbvie INC. | $15.88 | 2024 | |
| Circassia INC. | $14.68 | 2019 | |
| Inogen, INC. | $14.53 | 2024 | |
| Pulmonx Corporation | $13.07 | 2021 | |
| Ambu INC. | $11.03 | 2024 | |
| Biomerieux INC | $6.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Bakaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.